An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor EL).
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Oasmia Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 27 Apr 2016 According to an Oasmia Pharmaceuticals media release, results from this trial will form the basis of the marketing application to the US FDA anticipated to be submitted in the end of 2016/2017.
- 27 Apr 2016 Results of overall survival published in an Oasmia Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History